Post-COVID und die Lunge

 

 Buy Article Permissions and Reprints

Abstract

Most people recover completely after an acute infection with the novel corona virus SARS-CoV2. But some people continue to experience symptoms after their recovery. This phenomenon is called post-acute or long-COVID (from week 4 after the infection up to week 12) and persistent post-COVID (symptoms for effects that persist 12 or more weeks after onset). The exact processes that cause long COVID remain unknown.

Most of those patients suffer from long-term symptoms of lung damage, including breathlessness, coughing, fatigue and limited ability to exercise. Today, 18 months after the first infections in Europe we have access to the first practical guidelines for the long-/post-COVID syndrome. Further on first prospective studies analysing the incidence of post-COVID are now available.

In this review we will discuss some questions about treatment and follow up of patients suffering from pulmonary sequelae after their COVID-19 infection, based on the actual literature.

Publication History

Article published online:
20 October 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Koczulla A, Ankermann T, Behrends U. et al S1-Leitlinie Post-COVID/Long-COVID. AWMF-Register Nr. 020/027. Stand 16.07.2021; Im Internet: https://www.awmf.org/uploads/tx_szleitlinien/020-027l_S1_Post_COVID_Long_COVID_2021-07.pdf
  PubMedGoogle Scholar
• 2 Morin L, Savale L, Pham T. et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021; 325 (15) 1525-1534
  CrossrefPubMedGoogle Scholar
• 3 Prescott HC. Outcomes for patients following hospitalization for COVID-19. JAMA 2021; 325: 1511-1512
  CrossrefPubMedGoogle Scholar
• 4 Curci C, Negrini F, Ferrillo M. et al. Functional outcome after inpatient rehabilitation in post-intensive care unit COVID-19 patients: findings and clinical implications from a real-practice retrospective study. Eur J Phys Rehabil Med 2021; 57 (03) 443-450
  CrossrefPubMedGoogle Scholar
• 5 Han X, Fan Y, Alwalid O. et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021; 299: E177-E186
  CrossrefPubMedGoogle Scholar
• 6 Daugherty SE, Guo Y, Heath K. et al SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study. medRxiv 2021; DOI: 10.1101/2021.03.12.21253448. Im Internet: (Stand 22.07.2021) https://www.medrxiv.org/content/10.1101/2021.03.12.21253448v1
  CrossrefPubMedGoogle Scholar
• 7 Bhimraj A, Morgan RL, Shumaker AH. et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020; ciaa478 DOI: 10.1093/cid/ciaa478.
  CrossrefPubMedGoogle Scholar
• 8 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395: 1054-1062
  CrossrefPubMedGoogle Scholar
• 9 de Boer G, Braunstahl GJ, Hendriks R. et al. Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort. BMJ Open Respir Res 2021; 8 (01) e000758 DOI: 10.1136/bmjresp-2020-000758.
  CrossrefPubMedGoogle Scholar
• 10 Garcia-Pachon E, Grau-Delgado J, Soler-Sempere MJ. et al. Low prevalence of post-COVID-19 syndrome in patients with asthma. J Infect 2021; 82 (06) 276-316 DOI: 10.1016/j.jinf.2021.03.023.
  CrossrefPubMedGoogle Scholar
• 11 Underner M, Taille C, Peiffer G. et al. [COVID-19, severe asthma, and biologic]. Rev Mal Respir 2021; 38: 423-426 DOI: 10.1016/j.rmr.2021.03.002.
  CrossrefPubMedGoogle Scholar
• 12 Matsuyama S, Kawase M, Nao N. et al The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. BioRxiv 2020; Im Internet: (Stand 22.07.2021) DOI: 10.1101/2020.03.11.987016. https://www.biorxiv.org/content/10.1101/2020.03.11.987016v1
  CrossrefPubMedGoogle Scholar
• 13 Yamaya M, Nishimura H, Deng X. et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respiratory investigation 2020; 58: 155-168
  CrossrefPubMedGoogle Scholar
• 14 Ramakrishnan S, Nicolau Jr DV, Langford B. et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; 9 (07) 763-772 DOI: 10.1016/S2213-2600(21)00160-0.
  CrossrefPubMedGoogle Scholar
• 15 Kardos P, Dinh Q, Fuchs KH. et al. Leitlinie der deutschen gesellschaft für pneumologie und beatmungsmedizin zur diagnostik und therapie von erwachsenen patienten mit husten. Pneumologie 2019; 73: 143-180
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Arabi YM, Mandourah Y, Al-Hameed F. et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. American journal of respiratory and critical care medicine 2018; 197: 757-767
  CrossrefPubMedGoogle Scholar
• 17 Horby P, Lim WS, Emberson J. RECOVERY Collaborative Group. et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384 (08) 693-704
  CrossrefPubMedGoogle Scholar
• 18 Wang Y, Jiang W, He Q. et al Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. MedRxiv 2020; DOI: 10.1101/2020.03.06.20032342. Im Internet: (Stand 22.07.2021) https://www.medrxiv.org/content/10.1101/2020.03.06.20032342v1
  CrossrefPubMedGoogle Scholar
• 19 Myall KJ, Mukherjee B, Castanheira AM. et al. Persistent Post-COVID-19 Inflammatory Interstitial Lung Disease: An Observational Study of Corticosteroid Treatment. Ann Am Thorac Soc 2021; 18 (05) 799-806 DOI: 10.1513/AnnalsATS.202008-1002OC.
  CrossrefPubMedGoogle Scholar
• 20 Trabelsi K, Ammar A, Masmoudi L. et al. Sleep Quality and Physical Activity as Predictors of Mental Wellbeing Variance in Older Adults during COVID-19 Lockdown: ECLB COVID-19 International Online Survey. Int J Environ Res Public Health 2021; 18 (08) 4329 DOI: 10.3390/ijerph18084329.
  CrossrefPubMedGoogle Scholar
• 21 Heidbreder A, Sonnweber T, Stefani A. et al. Video-polysomnographic findings after acute COVID-19: REM sleep without atonia as sign of CNS pathology?. Sleep Med 2021; 80: 92-95 DOI: 10.1016/j.sleep.2021.01.051.
  CrossrefPubMedGoogle Scholar
• 22 Platz T. S2k-Leitlinie zur SARS-CoV-2, COVID-19 und (Früh-) Rehabilitation. AWMF Registernummer: 080-008. Stand 2020. Im Internet: (Stand 22.07.2021) https://www.awmf.org/leitlinien/detail/ll/080-008.html
  PubMedGoogle Scholar
• 23 Gloeckl R, Leitl D, Jarosch I. et al. Benefits of pulmonary rehabilitation in COVID-19–a prospective observational cohort study. ERJ Open Research 2021; 7 (02) 00108-2021
  CrossrefPubMedGoogle Scholar
• 24 Spielmanns M, Pekacka-Egli AM, Schoendorf S. et al. Effects of a Comprehensive Pulmonary Rehabilitation in Severe Post-COVID-19 Patients. Int J Environ Res Public Health 2021; 18 (05) 2695 DOI: 10.3390/ijerph18052695.
  CrossrefPubMedGoogle Scholar